Cataract senilis
Conditions
Interventions
Trade Name: Dicloabak
Product Name: Dicloabak
Pharmaceutical Form: Eye drops, solution
CAS Number: 15307-81-0
Other descriptive name: DICLOFENAC POTASSIUM
Trade Name: Nevanac
Product Name: Nevanac 1m
Sponsors
Raimo Tuuminen
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age 60-90 years Fullfills national criteria for cataract surgery Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 80
Exclusion criteria
Exclusion criteria: active wet AMD /planned anti-VEGF therapy prior retinal vein/artery occlusiion, retinal detachment, optic neuritis, vitreous hemorrhage, intraocular surgery. Myopia magna. Pregnancy. Alcohol misuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To study efficacy different nonsteroidal anti-inflammatory eye drops in management of post-operative inflammation and prevention of pseudophakic cystic macular edema after uncompplicated cataract surgery;Secondary Objective: To study efficacy different nonsteroidal anti-inflammatory eye drops in prevention of posterior capsule opacification after uncompplicated cataract surgery;Primary end point(s): Best corrected visual acuity, intraocular pressure, central retinal thickness, aqueous flare;Timepoint(s) of evaluation of this end point: 1 month | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Best corrected visual acuity, intraocular pressure, central retinal thickness, aqueous flare;Timepoint(s) of evaluation of this end point: 3 month | — |
Countries
Finland
Contacts
Public ContactClinical Trials Information
Raimo Tuuminen
Outcome results
None listed